In combination with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) ...

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, ...

Correlation between PD-L1 CPS and clinical outcomes in patients treated with first-line nivolumab plus chemotherapy for advanced gastric or gastroesophageal junction cancer: A multi-center ...

Frontline treatment with Tevimbra plus irinotecan, paclitaxel, oxaliplatin and 5-FU/leucovorin had promising efficacy and ...

adenocarcinoma with a PD-L1 expression (Combined Positive Score [CPS] ≥5). The European Commission (EC) has approved sugemalimab (brand name: Cejemly®) in combination with platinum-based ...

Now, data has arrived from Cohort B of the trial, a group of 33 patients who tested PD-L1-negative at enrolment – with a combined positive score [CPS] of less than 1. Among 31 evaluable subjects ...

recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, for the first-line treatment of patients with metastatic non-small cell lung cancer ...

recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, for the first-line treatment of patients with metastatic non-small cell lung cancer ...